chinese and foreign pharmaceutical and medical device companies collectively appeared at the ciftis, with many world-first and first-of-its-kind products on display
2024-09-14
한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
the 2024 china international fair for trade in services (hereinafter referred to as "ciftis") was held at the beijing national convention center and shougang park from september 12 to 16. the reporter of the paper noted that many world-renowned pharmaceutical and medical device companies brought innovative products and solutions to this ciftis, including not only "old friends" who have participated many times, but also many new faces who participated for the first time.
health and hygiene services exhibition area of ciftis
in terms of medical devices, domestic and foreign manufacturers such as siemens healthineers, ge healthcare, medtronic, united imaging healthcare, and mindray medical made their debut at the ciie and brought their leading innovative products.
ge healthcare is an old friend of the ciie. this is the fifth consecutive year that the company has participated in the exhibition and displayed a number of innovative achievements. according to ge healthcare, apex expert ct and the mobile x-ray machine "explorer" are the latest achievements of the beijing-tianjin-hebei ecosystem. the former can achieve accurate heart scans covering every detail of the coronary artery, myocardium, valves, large blood vessels, etc. under any heart rate conditions (high heart rate, irregular heart rate, free breathing). it is a revolutionary innovation in the field of ultra-high-end ct by the ge healthcare china team and global resources.
siemens healthineers made its debut at the ciie, bringing with it products such as the world's first innovative field strength magnetic resonance imaging, the world's first and only dual-source photon counting ct approved by nmpa through innovative medical devices.
another company participating in the ciie for the first time is medtronic, which brought more than 60 innovative exhibits and solutions. the exhibits cover cardiac rhythm management, cardiac surgery, cardiac ablation, structural heart disease, aortic and peripheral vascular health, coronary and renal artery sympathetic nerve ablation, orthopedics and neurosurgery, as well as surgery. among them, the aurora ev-icd system extravascular implantable cardioverter defibrillator places the electrode leads under the sternum, breaking the decades-long traditional treatment path of implantable cardioverter defibrillators, and strives to become a "portable aed" for patients at high risk of sudden cardiac death.
united imaging healthcare booth at the ciftis
as a representative manufacturer of domestic medical equipment, united imaging healthcare also displayed a number of products, including the world's first full-body clinical ultra-high field magnetic resonance umr jupiter 5t. according to the staff, the product has been settled in top hospitals and universities such as shanghai zhongshan, peking union medical college, fudan university, and tsinghua university. in the first half of this year, umr jupiter 5t was approved by fda 510 (k). since its launch, the product has always attracted the attention of global medical elites. this approval is expected to accelerate the landing of 5t in multiple markets such as the united states, and the ce certification of the product is also being accelerated.
many domestic and foreign pharmaceutical companies also appeared at this year's ciie. the most eye-catching ones were novo nordisk and eli lilly, the two giants in the field of glp-1 weight loss drugs. eli lilly directly displayed the gip-1/glp-1 dual-target drug tilpotide.
astrazeneca has participated in the ciftis for four consecutive years and this year set up a booth in the health and hygiene services exhibition area. although no specific drugs were directly exhibited, the three main lines of r&d innovation, industrial innovation ecology and sustainable development fully demonstrated astrazeneca's initiatives and achievements in increasing r&d investment, building an industrial innovation ecology, and promoting sustainable development. the reporter learned from astrazeneca that as of now, there are more than 200 projects in the chinese r&d pipeline, and it is expected that about 100 new drugs or new indications will be approved in china within 5 years. china's r&d pipeline projects will add 10-15 projects each year, and the synchronization rate with the global r&d pipeline has reached 100%.
hengrui medicine's exhibition area at this year's ciftis
as for domestic innovative pharmaceutical companies, hengrui medicine, beigene, innovent biologics and many other pharmaceutical companies have set up exhibition areas to introduce their innovative development through pictures and texts. this is the third time that innovent biologics has appeared at the ciftis, and the company's new bruton's tyrosine kinase (btk) inhibitor, obtunib, has appeared at the ciftis. the reporter of the paper learned that obtunib has been approved for marketing in china and singapore. obtunib has been approved for three indications in china, and all of them have been included in china's national medical insurance. in the first half of 2024, obtunib's revenue increased by 30% year-on-year to 420 million yuan, and increased by 48.8% year-on-year in the second quarter.
li xiaoxiao, reporter from the paper
(this article is from the paper. for more original information, please download the "the paper" app)
